Financhill
Sell
15

BIVI Quote, Financials, Valuation and Earnings

Last price:
$0.95
Seasonality move :
-17.62%
Day range:
$0.94 - $1.03
52-week range:
$0.62 - $7.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.83x
Volume:
215.8K
Avg. volume:
209.4K
1-year change:
-76.02%
Market cap:
$18M
Revenue:
--
EPS (TTM):
-$1.57

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BIVI
BioVie
-- -$0.36 -- -38.46% $6.00
ACXP
Acurx Pharmaceuticals
-- -$0.11 -- -59.62% $5.70
AXSM
Axsome Therapeutics
$140M -$1.04 61.04% -35.15% $177.05
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
OGEN
Oragenics
-- -- -- -- $1.00
TOVX
Theriva Biologics
-- -$0.47 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BIVI
BioVie
$0.97 $6.00 $18M -- $0.00 0% --
ACXP
Acurx Pharmaceuticals
$0.49 $5.70 $11.4M -- $0.00 0% --
AXSM
Axsome Therapeutics
$103.91 $177.05 $5.1B -- $0.00 0% 11.61x
NBY
NovaBay Pharmaceuticals
$0.63 $0.85 $3.6M -- $0.00 0% 0.16x
OGEN
Oragenics
$1.44 $1.00 $1M -- $0.00 0% 0.46x
TOVX
Theriva Biologics
$0.45 $7.00 $3.7M -- $0.00 0% 0.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BIVI
BioVie
-- 0.589 -- --
ACXP
Acurx Pharmaceuticals
-- 2.243 -- --
AXSM
Axsome Therapeutics
77.32% 0.872 3.16% 1.90x
NBY
NovaBay Pharmaceuticals
4.54% -0.044 1.51% 0.75x
OGEN
Oragenics
-- 0.068 -- --
TOVX
Theriva Biologics
-- -3.388 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BIVI
BioVie
-- -$3M -- -- -- -$1.3M
ACXP
Acurx Pharmaceuticals
-- -$2.1M -- -- -- -$2.1M
AXSM
Axsome Therapeutics
$111.7M -$55.5M -103.06% -309.19% -46.91% -$43.7M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

BioVie vs. Competitors

  • Which has Higher Returns BIVI or ACXP?

    Acurx Pharmaceuticals has a net margin of -- compared to BioVie's net margin of --. BioVie's return on equity of -- beat Acurx Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BIVI
    BioVie
    -- -$0.15 --
    ACXP
    Acurx Pharmaceuticals
    -- -$0.11 --
  • What do Analysts Say About BIVI or ACXP?

    BioVie has a consensus price target of $6.00, signalling upside risk potential of 518.3%. On the other hand Acurx Pharmaceuticals has an analysts' consensus of $5.70 which suggests that it could grow by 1070.64%. Given that Acurx Pharmaceuticals has higher upside potential than BioVie, analysts believe Acurx Pharmaceuticals is more attractive than BioVie.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIVI
    BioVie
    1 0 0
    ACXP
    Acurx Pharmaceuticals
    1 0 0
  • Is BIVI or ACXP More Risky?

    BioVie has a beta of 1.105, which suggesting that the stock is 10.465% more volatile than S&P 500. In comparison Acurx Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock BIVI or ACXP?

    BioVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Acurx Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie pays -- of its earnings as a dividend. Acurx Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIVI or ACXP?

    BioVie quarterly revenues are --, which are smaller than Acurx Pharmaceuticals quarterly revenues of --. BioVie's net income of -$2.8M is lower than Acurx Pharmaceuticals's net income of -$2.1M. Notably, BioVie's price-to-earnings ratio is -- while Acurx Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie is -- versus -- for Acurx Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIVI
    BioVie
    -- -- -- -$2.8M
    ACXP
    Acurx Pharmaceuticals
    -- -- -- -$2.1M
  • Which has Higher Returns BIVI or AXSM?

    Axsome Therapeutics has a net margin of -- compared to BioVie's net margin of -48.92%. BioVie's return on equity of -- beat Axsome Therapeutics's return on equity of -309.19%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIVI
    BioVie
    -- -$0.15 --
    AXSM
    Axsome Therapeutics
    91.94% -$1.22 $234.6M
  • What do Analysts Say About BIVI or AXSM?

    BioVie has a consensus price target of $6.00, signalling upside risk potential of 518.3%. On the other hand Axsome Therapeutics has an analysts' consensus of $177.05 which suggests that it could grow by 70.39%. Given that BioVie has higher upside potential than Axsome Therapeutics, analysts believe BioVie is more attractive than Axsome Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIVI
    BioVie
    1 0 0
    AXSM
    Axsome Therapeutics
    14 0 0
  • Is BIVI or AXSM More Risky?

    BioVie has a beta of 1.105, which suggesting that the stock is 10.465% more volatile than S&P 500. In comparison Axsome Therapeutics has a beta of 0.459, suggesting its less volatile than the S&P 500 by 54.053%.

  • Which is a Better Dividend Stock BIVI or AXSM?

    BioVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie pays -- of its earnings as a dividend. Axsome Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIVI or AXSM?

    BioVie quarterly revenues are --, which are smaller than Axsome Therapeutics quarterly revenues of $121.5M. BioVie's net income of -$2.8M is higher than Axsome Therapeutics's net income of -$59.4M. Notably, BioVie's price-to-earnings ratio is -- while Axsome Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie is -- versus 11.61x for Axsome Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIVI
    BioVie
    -- -- -- -$2.8M
    AXSM
    Axsome Therapeutics
    11.61x -- $121.5M -$59.4M
  • Which has Higher Returns BIVI or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to BioVie's net margin of -49.65%. BioVie's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIVI
    BioVie
    -- -$0.15 --
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About BIVI or NBY?

    BioVie has a consensus price target of $6.00, signalling upside risk potential of 518.3%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 35.98%. Given that BioVie has higher upside potential than NovaBay Pharmaceuticals, analysts believe BioVie is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIVI
    BioVie
    1 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is BIVI or NBY More Risky?

    BioVie has a beta of 1.105, which suggesting that the stock is 10.465% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

  • Which is a Better Dividend Stock BIVI or NBY?

    BioVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIVI or NBY?

    BioVie quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. BioVie's net income of -$2.8M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, BioVie's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIVI
    BioVie
    -- -- -- -$2.8M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns BIVI or OGEN?

    Oragenics has a net margin of -- compared to BioVie's net margin of --. BioVie's return on equity of -- beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BIVI
    BioVie
    -- -$0.15 --
    OGEN
    Oragenics
    -- -$3.60 --
  • What do Analysts Say About BIVI or OGEN?

    BioVie has a consensus price target of $6.00, signalling upside risk potential of 518.3%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 1983.54%. Given that Oragenics has higher upside potential than BioVie, analysts believe Oragenics is more attractive than BioVie.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIVI
    BioVie
    1 0 0
    OGEN
    Oragenics
    0 1 0
  • Is BIVI or OGEN More Risky?

    BioVie has a beta of 1.105, which suggesting that the stock is 10.465% more volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

  • Which is a Better Dividend Stock BIVI or OGEN?

    BioVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIVI or OGEN?

    BioVie quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. BioVie's net income of -$2.8M is lower than Oragenics's net income of -$2.2M. Notably, BioVie's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie is -- versus 0.46x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIVI
    BioVie
    -- -- -- -$2.8M
    OGEN
    Oragenics
    0.46x -- -- -$2.2M
  • Which has Higher Returns BIVI or TOVX?

    Theriva Biologics has a net margin of -- compared to BioVie's net margin of --. BioVie's return on equity of -- beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BIVI
    BioVie
    -- -$0.15 --
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About BIVI or TOVX?

    BioVie has a consensus price target of $6.00, signalling upside risk potential of 518.3%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1455.56%. Given that Theriva Biologics has higher upside potential than BioVie, analysts believe Theriva Biologics is more attractive than BioVie.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIVI
    BioVie
    1 0 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is BIVI or TOVX More Risky?

    BioVie has a beta of 1.105, which suggesting that the stock is 10.465% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

  • Which is a Better Dividend Stock BIVI or TOVX?

    BioVie has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIVI or TOVX?

    BioVie quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. BioVie's net income of -$2.8M is higher than Theriva Biologics's net income of -$4.3M. Notably, BioVie's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIVI
    BioVie
    -- -- -- -$2.8M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Robinhood Stock Keep Going Up?
Will Robinhood Stock Keep Going Up?

Commission-free online brokerage Robinhood (NASDAQ:HOOD) has served up massive gains…

Where Will Hershey Stock Be In 1 Year?
Where Will Hershey Stock Be In 1 Year?

Chocolate stocks used to be the epitome of sleepy stability,…

Where Will KNOT Stock Be In 1 Year?
Where Will KNOT Stock Be In 1 Year?

In the case of KNOT Offshore Partners (KNOP), most headlines…

Stock Ideas

Buy
63
Is NVDA Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 53x

Buy
60
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
48
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
92
BGL alert for Jul 3

Blue Gold [BGL] is down 20.3% over the past day.

Sell
18
CNC alert for Jul 3

Centene [CNC] is down 1.3% over the past day.

Sell
12
MOH alert for Jul 3

Molina Healthcare [MOH] is up 0.3% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock